Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 December 2017, 13:40 HKT/SGT
Share:
    

Source: Eisai
Eisai Launches Educational Materials for Understanding Dementia
And Thinking About What One Can Do for Elementary and Secondary School Students in Japan

TOKYO, Dec 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today.

Five types of materials have been created, an educational DVD, textbooks for elementary and secondary school students as well as guides for instructors for each textbook. The DVD is a live action drama that tells the story of a family whose grandmother has dementia, and the contents enable viewers to learn what is dementia, the feelings of someone with dementia, and how to interact with people with dementia. In addition to an outline of the DVD, the textbooks contain basic knowledge on the aging society and dementia, as well as points on how to interact with people with dementia. The textbooks can be used in lessons or group work. The contents of the guides for instructors include model lesson plans, question and answer ideas and reference materials, as well as worksheets that can be used in group work.

Yukimichi Imai MD., PhD., president of the Japanese Society for Dementia Care, Director of Wako Hospital and supervisor for these materials, stated: "he person that begins suffering dementia is the one who is most distressed, and changes in symptoms may occur depending on how their family and friends act. In addition, the number of people with dementia in 2025 is estimated to reach approximately 7 million, affecting one out of every five elderly people aged over 65. However, with the rise of the nuclear family, there are more and more children and students who have few opportunities to interact with people with dementia. We believe that learning about dementia at school and thinking together about the feelings of those with dementia and how to interact with them will be a very important first step in this era of a progressively aging society. I highly endorse Eisai' efforts in creating these educational materials to think about living together with dementia."

Hideki Hayashi, representative corporate officer, Japan Business and CIO, Eisai, commented: "During our work on building communities that co-exist with dementia in collaboration with local governments, medical and nursing care professionals as well as other stakeholders, we recognized the need for dementia education in the classroom, and created educational materials that can be used in lessons such as group work to think about the feelings of people with dementia and how to interact with them, as well as for gaining knowledge on dementia. Through these materials, we hope that children will become concerned about their own grandparents and the state of elderly people in public spaces as a member of the local community, and that this will spark responses such as consulting surrounding adults when they sense something is amiss."


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: